首頁 產業/市場分類 出版商一覽 Email 通知 GII媒體代理會議 公司簡介 聯絡我們
- English Japanese Korean
首頁 > 市場調查報告書 > 製藥 > 肥胖症治療 > 肥胖:全球藥品及外科治療市場趨勢
產業/市場分類
製藥 (4450)
肥胖症治療 (48)
非專利藥 (117)
疫苗 (167)
神經疾病 (175)
骨頭疾病治療 (40)
動物用醫藥 (18)
處方藥 (89)
規章 (107)
感染疾病 (316)
精神病 (80)
製藥企業 (500)
糖尿病 (157)
癌症 (837)
藥物開發 (1247)
DDS (173)
OTC 非處方藥 (147)
市場調查報告書

肥胖:全球藥品及外科治療市場趨勢

Obesity: The Worldwide Market for Pharmaceutical and Surgical Treatment

出版商 Kalorama Information
出版日期 2006年06月 商品編碼 45477
內容資訊 英文 160 pages
價格
US $ 995 PDF by E-mail (Single User License)
US $ 3500 Hard Copy
US $ 3800 PDF by E-mail (Single User License) & Hard Copy
US $ 7000 PDF by E-mail (Global Site License)


肥胖:全球藥品及外科治療市場趨勢 是由出版商Kalorama Information在2006年06月所出版的。 這份英文市場調查報告書包含160 pages 價格從美金995起跳。

目錄

Abstract

Despite troublesome safety problems with past entrants into this market, the veritable epidemic of overweight and obesity continues to make this sector an extremely attractive target for pharmaceutical developers. This new title provides a considered view of the market for medical interventions in the battle against obesity, including U.S. and worldwide market size and growth forecasts, competitive market share and extensive pharmaceutical pipeline information.

The report discusses both prescription and OTC drug markets and surgical interventions. Market size and growth rates are provided through 2010 for:

  • Prescription Appetite Suppressants
  • Prescription Lipase Inhibitors
  • OTC Appetite Suppressants
  • OTC Fat Substitutes
  • Surgical Intervetion (dollar- and procedure volumes)

Complete epidemilogical data, detailed descriptions of over 50 compounds in development for this sector, and profiles of 14 top suppliers are provided as well.

Table of Contents

Chapter One: Executive Summary

  • Scope and Methodology
  • Size and Growth of the Market
  • Issues and Trends Affecting Market
  • Leading Competitors

Chapter Two: Introduction

  • Overview of Obesity and Weight Management
    • Definition of Overweight and Obesity
    • Homeostatic Mechanisms Controlling Energy Balance
      • Linking Energy Stores in Body Fat with the Hypothalamus
      • Insulin as the Sensor of Energy Stores in Fat
      • Integration and Effect on Energy Balance
    • Regulation of Energy Expenditure and Food Intake
      • Energy Expenditure
      • Food Intake
    • Pathophysiology of Obesity
      • Obesity Disorder of the Homeostatic Control of Energy Balance
      • Genetic Factors
      • Food Intake
      • Physical Exercise
    • Causes of Overweight and Obesity
      • Genetics
      • Environmental
      • Socioeconomic
    • Health Risks
    • Economic Consequences
  • Demographics
  • Obesity Management

Chapter Three: Issues and Trends

  • Over-the Counter Xenical
  • Cortisol and Obesity
  • Weight and Height Trends
  • Educational Efforts of Physical Activity
    • Sedentary Behavior in Overweight and Obese Persons
    • Role of Physical Activity in Body Weight Regulation
    • Educating Patients About the Benefits of Activity
      • Cardiovascular and All-Cause Mortality
      • Cardiovascular Risk Factors
      • Fat and Muscle During Weight Loss
      • Physical and Psychologic Well-being
      • Long-term Weight Maintenance
  • Fat Gene Mapping Tool
  • Laser Melts Fat
  • Ciliary Neurotrophic Factor Update
  • Drinking and Obesity
  • Exercise Gene
  • Trends in Childhood Obesity
  • Effect of Modernization on Obesity
  • Insurance Coverage Issues
    • Medicare
    • Medicaid
    • Medicare Coverage of Bariatric Surgery
  • Selected Weight Loss Programs

Chapter Four: Prescription Pharmaceutical Market

  • Description of Products
    • Appetite Suppressants
    • Sympathomimetic Amine
    • Monoamine Reuptake Inhibitor
    • Lipase Inhibitors
  • Market Size and Growth
    • World Market
    • World Market and U.S. Market Analysis
    • Competitive Analysis

Chapter Five: Over-the-Counter Drugs

  • Overview
  • Description of Products
    • Appetite Suppressants
    • Noradrenergic Agents
    • Caffeine-based Agents
    • Benzocaine-Based Agents
    • Fat Substitutes
    • Others
    • 5HTP-Trptophan
    • Hoodia
  • Market Size and Growth
    • World Market
    • World Market and U.S. Market Analysis
    • Competitive Analysis

Chapter Six: Surgical Interventions

  • Overview
  • Description of Products
    • Restrictive Surgery
    • Combined Restrictive and Malabsorptive Surgery
  • Market Size and Growth
    • World Market
    • World Market and U.S. Market Analysis
    • Procedure Volumes

Chapter Seven: Pharmaceutical Research and Development

  • Overview
  • Description of Products
    • 5HT2-C Agonists
    • APD 356
    • WAY 629 & WAY 909
    • 5HT-6 Antagonists (BVT.5182)
    • Adiponectin (ACRP30 Famoxin)
    • Amylin Analogs (Symlin AC137)
    • Angiogenesis Inhibitors (TNP-470)
    • B-3AR Agonists
    • Botanical P57
    • Calpain-3
    • Cannabinoid-1 Receptor antagonists
    • Acomplia
    • L-000899055
    • SLV319
    • SR 147778
    • CCK-A Agonists
    • Cholesterol Metabolites (MSI-1436)
    • Cholesterol Transport Inhibitors (FM-VP4)
    • Ciliary Neurotrophic Factor (CNTF) (Axokine)
    • Extendin-4 (AC3174)
    • Fatty Acid Synthase Inhibitor (C75)
    • Fibroblast Growth Factor-1 Inhibitor
    • FIT Gene and Ion Channel (CSX121, CSX 102 and CXS-829)
    • Ghrelin Antagonist
    • Histamine-3 Antagonists
    • A-331440
    • NNC 0038-0000-1202
    • Human Growth Hormone Fragments (AOD 9604)
    • Leptin Agonists (CBT 1452)
    • Lipase Inhibitors
    • ATL 962
    • GT389-255
    • Melanin Concentrating Hormone-1 Receptor Antagonists
    • A-798
    • GW803430
    • NGX-1
    • SNAP 7941 SNAP94847
    • Melanocortin-4 Receptor Agonists
    • BIM-22103
    • NNC 70-619
    • Microsomal Triglyceride Transfer Protein (MTP) Inhibitor (SLx-4090)
    • Neuropeptide y2 Receptor Antagonist
    • Neuropeptide Y Agonist (TM30338 and TM30339)
    • Neuropeptide Y5 Receptor Antagonist (S-2367)
    • Nicotine Receptor Ligand (TC-2216/TC-2286)
    • Obestatin
    • Oleoyl-estrone
    • Oleoylethanolamide
    • Osmotin
    • Oxyntomodulin
    • Peroxisome Proliferator Activated Receptor (GW501516)
    • Peroxisome Proliferator Activated Receptor-Pan Agonist (DRL 11605)
    • Gut Hormone Peptide (PYY)
    • PPY3-36
    • AC 162352
    • Retinoid X Receptor: Peroxisome Proliferator Activated
    • Receptor Agonists (LG100268)
    • RIP140 Inhibitor
    • Selective Androgen Receptor Modulator (SARM) (Ostarine)
    • Stearoyl-COA Desaturase-1
    • Thyroid Hormone-B Receptor Agonist (KB-2115)
    • Vaccines (CYT009)
    • Others
    • BDC-03
    • BL-2040
    • HMR 1426
    • Orexin

Chapter Eight: World Market Summary

  • Overview
  • Total market Size and Forecast
  • Competitor Analysis

Chapter Nine: Corporate Profiles

  • Abbott Laboratories
  • Alizyme
  • Arena Pharmaceuticals
  • ChemGenex Pharmaceuticals
  • GlaxoSmithKline plc
  • Ligand Pharmaceuticals, Inc
  • Manhattan Pharmaceuticals, Inc
  • Merck & Company, Inc.
  • Metabolic Pharmaceuticals Limited
  • Novartis
  • Proctor & Gamble
  • Regeneron Pharmaceuticals Inc
  • Roche Group
  • Sanofi-Aventis

Appendix: Company Directory

Back to Top